BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced Tuesday that it has confirmed stability of its inhalable interferon coronavirus treatment through six months of real-time cold-temperature testing.
The testing was conducted at -20°C (-4°F) and +2-8°C (36-46°F), which represents standard freezer and refrigerator temperatures, and the interferon met all established stability testing criteria. The ability to ship, store and use the product at these temperatures greatly simplifies the distribution chain and patient use protocols, the company said.
“We are very pleased to see that our predictions for our patented inhalable interferon alpha2b product for the treatment of early-stage COVID-19 are being shown to be correct,” CEO Ahmad Doroudian said. “We believe our novel engineered interferon alpha 2b derived from our proprietary master cell bank offers important advantages that allows for a quick scale-up of manufacturing, especially in terms of logistics and cost of goods, which should enable us to meet potentially large demand (subject to regulatory clearance) once our treatment is ready for distribution.”
READ: BetterLife Pharma picks Equilab to manage trials of its inhaled coronavirus treatment, AP-003
The testing was performed at Longmont, Colorado-based Neva Analytics.
“We greatly accelerated our formulation development and testing protocols to make GMP product in record time during 2020,” Neva Vice President Libby Russell said. “We believe our time from formulation concept to GMP supplies was a modern record.”
Vancouver-based BetterLife believes that its inhaled IFN-α2b, AP-003, could lessen the severity and duration of COVID-19 and decrease the need for hospital admissions. The treatment is inhaled, so it targets the airways directly, unlike many other treatments being evaluated.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel